Petros Grivas, MD, PhD

Petros Grivas, MD, PhD, discusses the overall survival and quality-of-life findings from the JAVELIN Bladder 100 trial of avelumab as maintenance therapy for advanced bladder cancer.

Petros Grivas, MD, PhD, discusses how the JAVELIN Bladder 100 trial established avelumab as standard maintenance therapy for advanced bladder cancer.

Petros Grivas, MD, PhD, discusses challenges in cancer care in the bladder cancer setting.

Petros Grivas, MD, PhD, discusses the key trials of bladder cancer using immunotherapy he highlighted during a Case-Based Roundtable event.

Petros Grivas, MD, PhD, elaborates on some key unanswered questions on approaches to bladder cancer treatment he discussed with participants at a Case-Based Roundtable event.

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.

Petros Grivas, MD, PhD, discusses the design and end points of the phase 2 KEYNOTE-057 trial.

Petros Grivas, MD, PhD, discusses the phase 3 KEYNOTE-045 trial and the association between gene expression signatures and pembrolizumab in patients with advanced urothelial cancer.

Petros Grivas, MD, PhD, discusses the JAVELIN Bladder 100 trial of maintenance avelumab plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.